Chief Executive Officer
Mark co-founded Inhibrx with Brendan Eckelman and Quinn Deveraux in 2010 and has served as its Chief Executive Officer and Chief Financial Officer since the company’s inception. Mark also serves as the Chairman of Inhibrx’s Board of Directors. Mark has extensive expertise in the biotechnology industry with over thirty years of experience in executive management, investment management and executive recruiting, having built the executive teams of over forty start-up biotechnology and medical device companies. Prior to founding Inhibrx, Mark was the founder and Managing Partner of Efficacy Biotech Fund, a fund focused on strategic investment in public biotechnology companies.
EVP Corporate Strategy
Brendan is a co-founder of Inhibrx and serves as its Chief Scientific Officer and Executive Vice President of Corporate Strategy. Brendan heads research, overseeing several key functional areas spanning discovery to therapeutic development. Brendan is also a member of Inhibrx’s Board of Directors. In addition, he has critical responsibilities in corporate strategy and operations. Prior to founding Inhibrx, he was a Research Investigator in the biotherapeutics group at the Genomics Institute of the Novartis Research Foundation (GNF). He conducted his graduate research at the Sanford-Burnham-Prebys Medical Discovery Institute. Brendan received his Ph.D. in molecular pathology from the University of California, San Diego School of Medicine.
EVP Early Research
A co-founder of Inhibrx, Quinn leads target identification and validation, therapeutic lead selection and oversees the pipeline development strategy. Prior to founding Inhibrx, he spent 10 years at the Genomics Institute of the Novartis Research Foundation (GNF). Quinn led groups of Ph.D./M.D. level investigators in the conception and generation of novel target identification and validation platforms. Quinn was a key member of the team that transitioned the first GNF therapeutic antibody from bench-top to clinical trials. His research on cell death at the Stanford-Burnham-Prebys Medical Discovery Institute has been highly cited. Quinn received his Ph.D. in biochemistry from the University of Utah School of Medicine.
Klaus leads clinical development of the Inhibrx pipeline. Prior to joining Inhibrx, Klaus trained as a fellow of the M.D. Anderson Cancer Center. He then worked as a medical oncologist at the Banner M.D. Anderson Cancer Center, where he also served as the local principal investigator for clinical trials of cancer immunotherapy agents. Klaus’s scientific work at Genentech and the Genomics Institute of the Novartis Research Foundation (GNF) focused on drug discovery and predictive biomarker development. Klaus received the highest academic honors and was a Scholar of the German Merit Foundation. He received his M.D. and Ph.D. from the Friedrich-Alexander University of Erlangen in Germany.
Ashraf is responsible for the late stage activities required for commercialization of Inhibrx programs. He brings more than 20 years of experience in process development, technical operations, cGMP clinical manufacturing, commercialization and life cycle management of antibody therapeutics, vaccines, gene therapy, cell-based therapeutics and recombinant proteins. Prior to joining Inhibrx, Ashraf held executive and senior level positions with aTyr Pharma, Gilead Sciences, Genentech, and Merck & Co. Inc. He is the author of 55 peer-reviewed publications and his work has been presented at over 120 conferences. He is on the editorial board of the Biotechnology & Bioengineering and mAb journals. Ashraf received his Ph.D. in Chemical Engineering from The University of Birmingham (UK) and conducted post-doctoral studies with The University of Birmingham, Novo Nordisk, Merck Sharpe & Dohme and University College London.
John leads many aspects of research at Inhibrx, including protein engineering, assay development, and new technologies. He has been instrumental in developing the Inhibrx multi-specific antibody formats for conditional immune activation and generally oversees single domain antibody discovery projects. Prior to joining Inhibrx in 2010, John completed his postdoctoral training in Jack Dixon’s laboratory in the Department of Pharmacology at UCSD. John received his Ph.D. from the UCSD Biomedical Sciences Program, performing his thesis research in the laboratory of Guy Salvesen at the Sanford-Burnham-Prebys Medical Discover Institute.
Stuart leads process development and product manufacturing activities at Inhibrx, including sub-teams for upstream and downstream process development and analytical and formulation development. His team internally produces and characterizes materials for efficacy, PK, and exploratory and GLP toxicology studies and works with contract organizations for the production and release of materials for clinical studies. Prior to joining Inhibrx, Stuart led teams of engineers and scientists developing novel protein production platforms at Sutro Biopharma and Ambrx and worked on experimental growth factor, antibody, and antibody drug conjugate therapies. Stuart received his Ph.D. in chemical engineering from Cornell University.
Kelly leads the accounting and finance team at Inhibrx and is responsible for all internal and external reporting requirements, as well as day-to-day accounting activities. Kelly joined Inhibrx in October 2018, bringing with her over 15 years of experience in the life science industry. Prior to joining Inhibrx, Kelly held various accounting and finance positions of increasing responsibility with Apricus Biosciences, Inc., Hologic Inc., Gen-Probe, Inc., and Cytori Therapeutics, Inc. Kelly has a B.S. and M.S. in Accounting and is an active licensed Certified Public Accountant in the state of California.
Analeah leads translational research at Inhibrx and is responsible for non-clinical research in support of multiple IND filings annually. Prior to joining Inhibrx she spent ten years at Novartis in biologics drug discovery in multiple roles from oncology target validation through candidate optimization for varied therapeutic modalities, including antibody drug conjugates and immune activating agents. Analeah received her Ph.D. from the University of California, San Francisco in biochemistry and molecular biology and completed her postdoctoral research at the Genomics Institute for the Novartis Research Foundation.